FDA Expands Sogroya Approval; Record Obesity Rates in Kids; Cushing’s and Depression

(MedPage Today) — The FDA expanded the indication of the long-acting growth hormone somapacitan (Sogroya) to include very young children with idiopathic short stature, short stature born small for gestational age, or growth failure associated…